title: [Intraprostatic injection therapy in patients with benign prostatic syndrome].
abstract: Intraprostatic injection therapy is a minimally invasive treatment of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and could be a therapeutic alternative in increasingly older and co-morbid patients. Nowadays only botulinum neurotoxin A (BoNT/A), absolute ethanol, NX-1207 and PRX302 are of relevance but none of these substances has yet been authorized for treatment use (off-label use). There have been only three randomized, placebo-controlled trials (RCTs) for BoNT/A, whereas none exist for ethanol and the results of existing studies are inconsistent and without convincing proof of efficacy. NX-1207 is a protein with selective pro-apoptotic properties and non-inferiority compared to finasteride has been demonstrated. PRX302 is a modified proaerolysin that can be activated by prostate-specific antigen and is therefore (prostate) cell-specific. Safety and efficacy are well documented; however, intraprostatic injection therapy should presently only be performed in clinical trials, irrespective of the substance used.
authors: Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen, Justus-Liebig-Universität Gießen, Rudolf-Buchheim-Straße 7, 35392 Gießen, Deutschland. Th.B@gmx.de
authors: T
authors: T
authors: Bschleipfer
authors: T
authors: T
authors: Bach
authors: C
authors: C
authors: Gratzke
authors: S
authors: S
authors: Madersbacher
authors: M
authors: M
authors: Oelke
mesh_terms: D001427:Bacterial Toxins / Q000008:administration & dosage*; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D000431:Ethanol / Q000008:administration & dosage*; D006801:Humans; D015552:Injections, Intralesional; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D008297:Male; D052899:Pore Forming Cytotoxic Proteins / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D001427:Bacterial Toxins; C518473:PRX302; D052899:Pore Forming Cytotoxic Proteins; D000431:Ethanol; D019274:Botulinum Toxins, Type A